{"id":"insulin-aspart-70","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201496","moleculeType":"Protein"},"_dailymed":{"setId":"5d9f0e10-edb9-4960-bd62-cf406e75bbe7","title":"INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30 (INSULIN ASPART) INJECTION, SUSPENSION [REMEDYREPACK INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin Aspart is a recombinant human insulin analog with a faster onset and shorter duration of action than regular human insulin. The '70' designation indicates this is a biphasic formulation containing 70% intermediate-acting insulin (NPH) and 30% rapid-acting insulin aspart. It mimics the body's natural insulin secretion pattern by providing both basal and mealtime glucose control.","oneSentence":"Insulin Aspart 70 is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood glucose levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:07.419Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT06607224","phase":"NA","title":"Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.","status":"COMPLETED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2022-01-10","conditions":"Diabetes Mellitus Type 2, Hospitalization","enrollment":40},{"nctId":"NCT04460326","phase":"PHASE3","title":"Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2020-12-07","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":137},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT00671008","phase":"","title":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-12","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT00101751","phase":"PHASE4","title":"INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":4877},{"nctId":"NCT01486862","phase":"PHASE4","title":"Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT00476437","phase":"PHASE3","title":"Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":81},{"nctId":"NCT02408120","phase":"PHASE4","title":"Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-10","conditions":"Diabetes Mellitus, Type 2","enrollment":226},{"nctId":"NCT03737240","phase":"PHASE3","title":"IDegLira HIGH Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-01-15","conditions":"Diabetes Mellitus","enrollment":145},{"nctId":"NCT03359837","phase":"PHASE4","title":"Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":384},{"nctId":"NCT03916601","phase":"PHASE1","title":"Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-12-13","conditions":"Type 1 Diabetes","enrollment":52},{"nctId":"NCT01293396","phase":"PHASE4","title":"Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":20},{"nctId":"NCT04726657","phase":"NA","title":"Comparison of Two Biphasic Insulin Regimens","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2016-01-18","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT03862690","phase":"","title":"A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2020-05-28","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT04226105","phase":"PHASE3","title":"Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Geropharm","startDate":"2020-01-20","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":264},{"nctId":"NCT00821795","phase":"PHASE4","title":"Veterans Inpatient Insulin Study and Transition to Outpatient Therapy","status":"COMPLETED","sponsor":"Dennis G. Karounos, M.D.","startDate":"2009-03-11","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT04184492","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-04-15","conditions":"Clamp Study","enrollment":34},{"nctId":"NCT01966978","phase":"PHASE4","title":"The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-11","conditions":"Diabetes Mellitus, Type 2, Diabetes","enrollment":157},{"nctId":"NCT02987751","phase":"PHASE4","title":"A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","startDate":"2016-12-29","conditions":"Type2 Diabetes","enrollment":200},{"nctId":"NCT02582242","phase":"PHASE4","title":"Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-10-19","conditions":"Diabetes, Type 2 Diabetes Mellitus","enrollment":437},{"nctId":"NCT02762578","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":543},{"nctId":"NCT02453685","phase":"PHASE4","title":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT01059812","phase":"PHASE3","title":"A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-02-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":424},{"nctId":"NCT01009580","phase":"PHASE3","title":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":447},{"nctId":"NCT02467920","phase":"PHASE4","title":"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2015-08","conditions":"Type 2 Diabetes Mellitus","enrollment":349},{"nctId":"NCT02449603","phase":"PHASE4","title":"Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":150},{"nctId":"NCT02648217","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-01-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":263},{"nctId":"NCT03374774","phase":"","title":"A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":516},{"nctId":"NCT00659282","phase":"","title":"Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-09-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":57610},{"nctId":"NCT00232583","phase":"NA","title":"Preservation of Beta-cell Function in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2003-11","conditions":"Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT01538511","phase":"PHASE1","title":"Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT01589653","phase":"PHASE4","title":"Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-05-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":155},{"nctId":"NCT00613951","phase":"PHASE2","title":"Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":182},{"nctId":"NCT00184600","phase":"PHASE3","title":"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT00564668","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-06-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":126},{"nctId":"NCT01467401","phase":"PHASE4","title":"Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":292},{"nctId":"NCT01523041","phase":"PHASE1","title":"Comparison of Two Formulations of Biphasic Insulin Aspart 70","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-11-03","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT01704378","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-04-18","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT00184626","phase":"PHASE4","title":"Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-09-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":97},{"nctId":"NCT01527539","phase":"PHASE3","title":"Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-11-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT00617565","phase":"PHASE3","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-07-08","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":219},{"nctId":"NCT01519674","phase":"PHASE4","title":"Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT01527565","phase":"PHASE1","title":"Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-01-20","conditions":"Diabetes, Healthy","enrollment":30},{"nctId":"NCT01536626","phase":"","title":"Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":211},{"nctId":"NCT00592969","phase":"PHASE4","title":"Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":164},{"nctId":"NCT01427920","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":348},{"nctId":"NCT01697631","phase":"PHASE4","title":"Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-07-22","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":131},{"nctId":"NCT00791895","phase":"PHASE4","title":"Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-06-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":102},{"nctId":"NCT01618214","phase":"PHASE4","title":"Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT01123980","phase":"PHASE4","title":"Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":521},{"nctId":"NCT01486381","phase":"PHASE3","title":"Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-03-20","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT01467375","phase":"PHASE3","title":"Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-01-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT00469092","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":480},{"nctId":"NCT01174303","phase":"PHASE1","title":"A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT01051102","phase":"PHASE1","title":"Effect of NN5401 in Japanese Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":21},{"nctId":"NCT00993096","phase":"PHASE1","title":"Investigation of the Response Relationship of NN5401 in Type 1 Diabetics","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":33},{"nctId":"NCT00842361","phase":"PHASE2","title":"Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":66},{"nctId":"NCT01542424","phase":"","title":"An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-03","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":1889},{"nctId":"NCT00869908","phase":"","title":"Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":66726},{"nctId":"NCT01068652","phase":"PHASE4","title":"Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":403},{"nctId":"NCT03018665","phase":"PHASE4","title":"A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2017-02","conditions":"Diabetes Mellitus, Type 2","enrollment":200},{"nctId":"NCT00097877","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":293},{"nctId":"NCT00775736","phase":"","title":"Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":611},{"nctId":"NCT00605111","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":193},{"nctId":"NCT00097279","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":230},{"nctId":"NCT01536639","phase":"","title":"Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":454},{"nctId":"NCT00598793","phase":"PHASE3","title":"Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":242},{"nctId":"NCT00657319","phase":"","title":"Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":3495},{"nctId":"NCT00665093","phase":"","title":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":1569},{"nctId":"NCT00696995","phase":"","title":"An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":509},{"nctId":"NCT01527656","phase":"PHASE1","title":"Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12","conditions":"Diabetes, Healthy","enrollment":40},{"nctId":"NCT00619697","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":260},{"nctId":"NCT00600626","phase":"PHASE3","title":"Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":394},{"nctId":"NCT01487798","phase":"PHASE4","title":"Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":170},{"nctId":"NCT01486875","phase":"","title":"Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1155},{"nctId":"NCT01487811","phase":"PHASE1","title":"Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-05","conditions":"Diabetes, Healthy","enrollment":50},{"nctId":"NCT00824668","phase":"PHASE1","title":"Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT00825253","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT00313001","phase":"PHASE3","title":"Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":373},{"nctId":"NCT01536600","phase":"","title":"Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":33010},{"nctId":"NCT00624364","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":140},{"nctId":"NCT00280046","phase":"PHASE3","title":"Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":307},{"nctId":"NCT01548235","phase":"","title":"Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":423},{"nctId":"NCT00612599","phase":"PHASE3","title":"Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":75},{"nctId":"NCT00600366","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":71},{"nctId":"NCT00184561","phase":"PHASE4","title":"Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-07","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":321},{"nctId":"NCT01536028","phase":"PHASE1","title":"Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":32},{"nctId":"NCT00318786","phase":"PHASE3","title":"Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":289},{"nctId":"NCT01526941","phase":"PHASE1","title":"Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-05","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":27},{"nctId":"NCT01526980","phase":"PHASE2","title":"Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":31},{"nctId":"NCT00184574","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":603},{"nctId":"NCT01524809","phase":"PHASE1","title":"Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":26},{"nctId":"NCT01620333","phase":"PHASE1","title":"Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2000-02","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT01620424","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":10},{"nctId":"NCT01707160","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1995-11","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT01520831","phase":"PHASE1","title":"Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-04","conditions":"Diabetes, Healthy","enrollment":35},{"nctId":"NCT01467323","phase":"PHASE3","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1998-04","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":303},{"nctId":"NCT01697618","phase":"PHASE2","title":"Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1997-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":13},{"nctId":"NCT01520818","phase":"PHASE3","title":"Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2000-03","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":666}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BLOOD CREATININE INCREASED"},{"count":1,"reaction":"BLOOD GLUCOSE DECREASED"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"GOUT"},{"count":1,"reaction":"HAEMOLYTIC ANAEMIA"},{"count":1,"reaction":"HYPOGLYCAEMIA"},{"count":1,"reaction":"PLATELET COUNT DECREASED"},{"count":1,"reaction":"WHEEZING"}],"_approvalHistory":[],"publicationCount":39,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Novomix 70"],"phase":"marketed","status":"active","brandName":"Insulin Aspart 70","genericName":"Insulin Aspart 70","companyName":"Medical University of Graz","companyId":"medical-university-of-graz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin Aspart 70 is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to facilitate glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}